- Home
- NIU vs HURA Comparison
NIU vs HURA Comparison
Compare NIU & HURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NIU | HURA |
|---|---|---|
| Founded | 2014 | 2009 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Auto Manufacturing | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 147.5M | 160.5M |
| IPO Year | 2018 | 2010 |
Fundamental Metrics
Financial Performance| Metric | NIU | HURA |
|---|---|---|
| Price | $1.89 | $1.99 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 4 |
| Target Price | $2.55 | ★ $8.04 |
| AVG Volume (30 Days) | 155.7K | ★ 250.0K |
| Earning Date | 11-16-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 47.93 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $20.29 | N/A |
| Revenue Next Year | $22.76 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.79 | $0.41 |
| 52 Week High | $4.53 | $3.43 |
Technical Indicators
Market Signals| Indicator | NIU | HURA |
|---|---|---|
| Relative Strength Index (RSI) | 42.05 | 51.91 |
| Support Level | $1.81 | $1.83 |
| Resistance Level | $2.04 | $2.22 |
| Average True Range (ATR) | 0.05 | 0.13 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 18.18 | 57.14 |
Price Performance
Historical ComparisonAbout NIU Niu Technologies
Niu Technologies designs, manufactures, and sells high-performance electric motorcycles, scooters, bicycles, and kick-scooters. The company has a product portfolio consisting of electric motorcycles, mopeds, and bicycle series, including the NQi, MQi, UQi, FQi series, and others, and micro-mobility series, including the kick-scooter series KQi and the e-bike series BQi. The company's principal operations and geographic markets are predominantly in the People's Republic of China. It also generates revenue from Europe and other regions.
About HURA TuHURA Biosciences Inc.
TuHURA Biosciences Inc is a phase 3 clinical stage immuno-oncology company with three distinct technologies focused on the development of novel therapeutics designed to overcome primary and acquired resistance to cancer immunotherapies. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. The company operates in one reportable segment, which includes all activities related to advancing therapies for cancer treatment.